Rebamipide Reprograms Hepatic Networks to Prevent and Reverse Metabolic-Dysfunction-Associated Steatotic Liver Disease: Multi-Omics Insights and Histological Validation
These findings demonstrate Rebamipide's dual-phase, multi-targeted mechanism: early protection against diet-induced metabolic injury and robust reversal of established MASLD pathology. The identified protein triad (Mttp, Cyp2c6, Hspa9) and associated pathways provide novel biomarker candidates and mechanistic insight supporting Rebamipide's repurposing as a therapeutic for metabolic liver disease.
Authors
- Essa M. Saied (ORCID: https://orcid.org/0000-0002-7342-6200)
- Doaa I. Mohamed
- Tarek A. Yousef (ORCID: https://orcid.org/0000-0003-3039-7646)
- Abdullah Al-Dakhil (ORCID: https://orcid.org/0000-0002-3193-7328)
- Ali H. Abu Almaaty (ORCID: https://orcid.org/0000-0001-9056-0228)
- Hebatallah H. Abo Nahas (ORCID: https://orcid.org/0009-0004-6754-5045)
- I. M. EL-Deen I. M. EL-Deen
- Hatem Adel M. Sembawa
Institutions
- Ain Shams University (EG)
- Suez Canal University (EG)
- Umm al-Qura University (SA)
- Imam Mohammad ibn Saud Islamic University (SA)
- Humboldt-Universität zu Berlin (DE)
- Port Said University (EG)
Publication Details
- Journal
- Pharmaceuticals
- Published
- 2026-03-31
- DOI
- https://doi.org/10.3390/ph19040559
- Primary Topic
- Liver Disease Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00